Showing 3981-3990 of 8897 results for "".
- Roflumilast 0.05% Gains FDA Approval for Children 2-5 with ADhttps://practicaldermatology.com/news/roflumilast-005-gains-fda-approval-for-children-2-5-with-ad/2483862/The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% (Zoryve®, Arcutis Biotherapeutics) for the treatment of mild-to-moderate atopic dermatitis (AD) in children 2 to 5 years old. This once-daily topical phosphodiesterase-4 (PDE4) inhibitor
- FDA Approves Guselkumab for Children 6 and Older With PsOhttps://practicaldermatology.com/news/fda-approves-guselkumab-for-children-6-and-older-with-pso/2483604/The US Food and Drug Administration (FDA) has approved guselkumab (Tremfya®, Johnson & Johnson) for the treatment of children 6 and older, weighing at least 40 kg, with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA), making it the
- FDA Approves Remibrutinib for Adults With CSUhttps://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/The US Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido, Novartis) as the first oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of chronic spontaneous urticaria (CSU) in adults whose symptoms persist despite H1 antihistamine the
- Study: Ruxolitinib Cream Same or Better Than Triamcinolone for Mild to Moderate ADhttps://practicaldermatology.com/news/ruxolitinib-cream-triamcinolone-for-mild-to-moderate-ad/2483574/New analysis of phase 2 data indicates ruxolitinib cream 1.5% may offer comparable or superior efficacy to midpotency corticosteroid triamcinolone 0.1% cream in adult patients with long-standing mild to moderate atopic dermatitis (AD).
- Meta-analysis: Severe Childhood Sunburns Triple Risk of cSCChttps://practicaldermatology.com/news/meta-analysis-severe-childhood-sunburns-triple-risk-of-cscc/2483566/Data from a new meta-analysis showed an association between severe sunburn history and increased risk of cutaneous squamous cell carcinoma (cSCC) across all life stages. Researchers publishing in JAMA Dermatology use
- Roflumilast Phase 2 Results for Children Consistent With Phase 3 Adult Trialshttps://practicaldermatology.com/news/roflumilast-phase-2-results-for-children-consistent-with-phase-3-adult-trials/2483558/Once-daily roflumilast cream 0.3% was well tolerated and improved signs and symptoms of psoriasis in children 2 to 11 years old in two 4-week, phase 2, open-label, maximal usage pharmacokinetic and safety studies, according to an article published in Pediatric Dermatology. The res
- Study Quantifies Cutaneous Reaction Risks of Some CKD Treatmentshttps://practicaldermatology.com/news/study-quantifies-cutaneous-reaction-risks-of-some-ckd-treatments/2483518/A newly validated risk prediction model in The Lancet Rheumatology could assist practitioners in estimating a patient’s short-term risk of developing severe cutaneous adverse reactions (SCARs) following initiation of allopuri
- Analysis: Dupilumab-Related Adverse Events Less Common in Black Adults With ADhttps://practicaldermatology.com/news/analysis-dupilumab-related-adverse-events-less-common-in-black-adults-with-ad/2483504/A retrospective chart review in the Journal of Drugs in Dermatology yielded insights into dupilumab-associated adverse events (d-AEs) in Black and African American (AA) adults treated for atopic dermatitis (AD). The st
- Study: Nicotinamide Linked with Reduced Skin Cancer Risk Following First Diagnosishttps://practicaldermatology.com/news/va-study-finds-nicotinamide-reduces-skin-cancer-risk-after-first-diagnosis/2483481/A large Veterans Affairs (VA) cohort study has found that nicotinamide supplementation is associated with a reduced risk of subsequent skin cancers, particularly when initiated after a patient’s first diagnosis. Researchers on t
- FDA Approves Topical Ruxolitinib for AD in Children Aged 2 and Uphttps://practicaldermatology.com/news/fda-approves-topical-ruxolitinib-for-ad-in-children-aged-2-and-up/2483445/The US Food and Drug Administration (FDA) has approved ruxolitinib cream 1.5% (Opzelura) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis (AD) in non-immunocompromised children ages 2 and older whose disease is inadequate